tiprankstipranks
Elevance Health (GB:0HG8)
LSE:0HG8
UK Market
0HG8
Elevance Health
RESEARCH TOOLSreports

Elevance Health (0HG8) Share Forecast & Price Target

1 Followers
See the Price Targets and Ratings of:

0HG8 Analyst Ratings

Moderate Buy
17Ratings
Moderate Buy
10 Buy
7 Hold
0 Sell
Based on 17 analysts giving stock ratings to
Elevance
Health
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

0HG8 Stock 12 Month Forecast

Average Price Target

$443.60
▲(11.97% Upside)
Based on 17 Wall Street analysts offering 12 month price targets for Elevance Health in the last 3 months. The average price target is $443.60 with a high forecast of $488.00 and a low forecast of $393.00. The average price target represents a 11.97% change from the last price of $396.17.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"289":"$289","339":"$339","389":"$389","439":"$439","489":"$489"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":488,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$488.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":443.6,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$443.60</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":393,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$393.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[289,339,389,439,489],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.259,407.9313846153846,414.6037692307692,421.2761538461539,427.9485384615385,434.6209230769231,441.2933076923077,447.96569230769234,454.63807692307694,461.31046153846154,467.98284615384614,474.6552307692308,481.3276153846154,{"y":488,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.259,404.516,407.773,411.03000000000003,414.28700000000003,417.54400000000004,420.80100000000004,424.058,427.315,430.572,433.829,437.086,440.343,{"y":443.6,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,401.259,400.6236923076923,399.98838461538463,399.3530769230769,398.71776923076925,398.08246153846153,397.44715384615387,396.81184615384615,396.1765384615385,395.54123076923076,394.9059230769231,394.2706153846154,393.6353076923077,{"y":393,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":311.465,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":326.001,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":310.53,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":329.96,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":347.761,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":338.55,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":290.711,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":295.952,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":371.3,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":399.881,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":410.195,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":377.36,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":401.259,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$488.00Average Price Target$443.60Lowest Price Target$393.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on GB:0HG8
Lance Wilkes
Bernstein
Bernstein
$488
Buy
23.18%
Upside
Reiterated
09/09/26
Elevance Health (ELV) Receives a Buy from Bernstein
Argus Research Analyst forecast on GB:0HG8
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Barclays Analyst forecast on GB:0HG8
Andrew Mok CFA
Barclays
Barclays
$457
Buy
15.35%
Upside
Assigned
07/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Elevance Health (NYSE: ELV) and InnovAge Holding (NASDAQ: INNV)
Morgan Stanley Analyst forecast on GB:0HG8
Erin Wright
Morgan Stanley
Morgan Stanley
$404
Hold
1.98%
Upside
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on GB:0HG8
Whit Mayo
Leerink Partners
Leerink Partners
$364→$395
Hold
-0.30%
Downside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen Analyst forecast on GB:0HG8
Ryan Langston
TD Cowen
TD Cowen
$465
Buy
17.37%
Upside
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on GB:0HG8
David S Macdonald
Truist Financial
Truist Financial
$475
Buy
19.90%
Upside
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on GB:0HG8
David Windley
Jefferies
Jefferies
$391→$450
Buy
13.59%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Wells Fargo Analyst forecast on GB:0HG8
Stephen Baxter
Wells Fargo
Wells Fargo
$492→$473
Buy
19.39%
Upside
Assigned
07/16/26
Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo
Bank of America Securities Analyst forecast on GB:0HG8
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$460
Buy
16.11%
Upside
Reiterated
07/16/26
Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals
Robert W. Baird Analyst forecast on GB:0HG8
Michael Ha
Robert W. Baird
Robert W. Baird
$331→$393
Hold
-0.80%
Downside
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on GB:0HG8
Amit Daryanani
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on GB:0HG8
Ben Hendrix
RBC Capital
RBC Capital
$439→$424
Hold
7.02%
Upside
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on GB:0HG8
Scott Fidel
Goldman Sachs
Goldman Sachs
$370→$395
Hold
-0.30%
Downside
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Guggenheim Analyst forecast on GB:0HG8
Jason Cassorla
Guggenheim
Guggenheim
$399→$455
Buy
14.85%
Upside
Reiterated
07/15/26
Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Bernstein Analyst forecast on GB:0HG8
Lance Wilkes
Bernstein
Bernstein
$488
Buy
23.18%
Upside
Reiterated
09/09/26
Elevance Health (ELV) Receives a Buy from Bernstein
Argus Research Analyst forecast on GB:0HG8
David Toung
Argus Research
Argus Research
―
Hold
―
Reiterated
08/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Shenzhen Edge Medical Co., Ltd. Class H (HKEX: HK:2675), Elevance Health (NYSE: ELV) and 4DMedical Ltd (ASX: AU:4DX)
Barclays Analyst forecast on GB:0HG8
Andrew Mok CFA
Barclays
Barclays
$457
Buy
15.35%
Upside
Assigned
07/20/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Iovance Biotherapeutics (NASDAQ: IOVA), Elevance Health (NYSE: ELV) and InnovAge Holding (NASDAQ: INNV)
Morgan Stanley Analyst forecast on GB:0HG8
Erin Wright
Morgan Stanley
Morgan Stanley
$404
Hold
1.98%
Upside
Assigned
07/17/26
Erin Wright Maintains Hold Rating on Elevance with Unchanged $404 Price Target Amid Mixed Results and Cautious Outlook
Leerink Partners Analyst forecast on GB:0HG8
Whit Mayo
Leerink Partners
Leerink Partners
$364→$395
Hold
-0.30%
Downside
Reiterated
07/17/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: 10x Genomics (NASDAQ: TXG), Elevance Health (NYSE: ELV) and Johnson & Johnson (NYSE: JNJ)
TD Cowen Analyst forecast on GB:0HG8
Ryan Langston
TD Cowen
TD Cowen
$465
Buy
17.37%
Upside
Reiterated
07/17/26
TD Cowen Keeps Their Buy Rating on Elevance Health (ELV)
Truist Financial Analyst forecast on GB:0HG8
David S Macdonald
Truist Financial
Truist Financial
$475
Buy
19.90%
Upside
Reiterated
07/16/26
Elevance Health price target raised to $475 from $450 at TruistElevance Health price target raised to $475 from $450 at Truist
Jefferies Analyst forecast on GB:0HG8
David Windley
Jefferies
Jefferies
$391→$450
Buy
13.59%
Upside
Reiterated
07/16/26
Analysts Offer Insights on Healthcare Companies: Avita Medical (NASDAQ: RCEL), Tenaya Therapeutics (NASDAQ: TNYA) and Elevance Health (NYSE: ELV)
Wells Fargo Analyst forecast on GB:0HG8
Stephen Baxter
Wells Fargo
Wells Fargo
$492→$473
Buy
19.39%
Upside
Assigned
07/16/26
Elevance Health price target raised to $492 from $391 at Wells FargoElevance Health price target raised to $492 from $391 at Wells Fargo
Bank of America Securities Analyst forecast on GB:0HG8
Kevin Fischbeck
Bank of America Securities
Bank of America Securities
$460
Buy
16.11%
Upside
Reiterated
07/16/26
Fischbeck Reiterates Buy on Elevance Health, Keeps $460 Price Target Unchanged Amid Cautious Guidance and Improving Fundamentals
Robert W. Baird Analyst forecast on GB:0HG8
Michael Ha
Robert W. Baird
Robert W. Baird
$331→$393
Hold
-0.80%
Downside
Reiterated
07/16/26
Elevance Health price target raised to $393 from $331 at BairdElevance Health price target raised to $393 from $331 at Baird
Evercore ISI Analyst forecast on GB:0HG8
Amit Daryanani
Evercore ISI
Evercore ISI
―
Hold
―
Reiterated
07/15/26
Regulatory and Cost Pressures Balance Solid Fundamentals: Amit Daryanani Maintains Hold on Elevance Health
RBC Capital Analyst forecast on GB:0HG8
Ben Hendrix
RBC Capital
RBC Capital
$439→$424
Hold
7.02%
Upside
Reiterated
07/15/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Atai Beckley N.V. (NASDAQ: ATAI), Alnylam Pharma (NASDAQ: ALNY) and Elevance Health (NYSE: ELV)
Goldman Sachs Analyst forecast on GB:0HG8
Scott Fidel
Goldman Sachs
Goldman Sachs
$370→$395
Hold
-0.30%
Downside
Reiterated
07/15/26
Elevance Health price target raised to $395 from $370 at Goldman SachsElevance Health price target raised to $395 from $370 at Goldman Sachs
Guggenheim Analyst forecast on GB:0HG8
Jason Cassorla
Guggenheim
Guggenheim
$399→$455
Buy
14.85%
Upside
Reiterated
07/15/26
Guggenheim Sticks to Their Buy Rating for Elevance Health (ELV)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARDXArdelyx
ZVRAZevra Therapeutics
HROWHarrow Health
KURAKura Oncology
SNDXSyndax Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Elevance Health

3 Months
David S MacdonaldTruist Financial
Success Rate
13/20 ratings generated profit
65%
Average Return
+2.83%
Copying David S Macdonald's trades and holding each position for 3 Months would result in 65.00% of your transactions generating a profit, with an average return of +2.83% per trade.
1 Year
A.J. RiceUBS
Success Rate
24/30 ratings generated profit
80%
Average Return
+19.94%
Copying A.J. Rice's trades and holding each position for 1 Year would result in 80.00% of your transactions generating a profit, with an average return of +19.94% per trade.
2 Years
A.J. RiceUBS
Success Rate
27/30 ratings generated profit
90%
Average Return
+39.54%
Copying A.J. Rice's trades and holding each position for 2 Years would result in 90.00% of your transactions generating a profit, with an average return of +39.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0HG8 Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
0
0
0
0
0
Buy
29
30
27
21
16
Hold
9
9
9
9
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
38
39
36
30
24
In the current month, 0HG8 has received 16 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. 0HG8 average Analyst price target in the past 3 months is 443.60.
Each month's total comprises the sum of three months' worth of ratings.

0HG8 Financial Forecast

0HG8 Earnings Forecast

Next quarter’s earnings estimate for 0HG8 is $4.66 with a range of $4.55 to $4.99. The previous quarter’s EPS was $7.45. 0HG8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HG8 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 0HG8 is $4.66 with a range of $4.55 to $4.99. The previous quarter’s EPS was $7.45. 0HG8 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year 0HG8 has Performed in-line its overall industry.

0HG8 Sales Forecast

Next quarter’s sales forecast for 0HG8 is $49.30B with a range of $47.79B to $51.00B. The previous quarter’s sales results were $50.47B. 0HG8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HG8 has Performed in-line its overall industry.
Next quarter’s sales forecast for 0HG8 is $49.30B with a range of $47.79B to $51.00B. The previous quarter’s sales results were $50.47B. 0HG8 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year 0HG8 has Performed in-line its overall industry.

0HG8 Stock Forecast FAQ

What is GB:0HG8’s average 12-month price target, according to analysts?
Based on analyst ratings, Elevance Health’s 12-month average price target is 443.60.
    What is GB:0HG8’s upside potential, based on the analysts’ average price target?
    Elevance Health has 11.97% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Elevance Health a Buy, Sell or Hold?
          Elevance Health has a consensus rating of Moderate Buy, which is based on 10 buy ratings, 7 hold ratings and 0 sell ratings.
            What is Elevance Health’s share price target?
            The average share price target for Elevance Health is 443.60. This is based on 17 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $488.00 ,and the lowest forecast is $393.00. The average share price target represents 11.97% Increase from the current price of $396.17.
              What do analysts say about Elevance Health?
              Elevance Health’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 17 Wall Streets Analysts.
                How can I buy shares of Elevance Health?
                To buy shares of GB:0HG8, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.